HLB Life Science Co., Ltd. (067630.KQ)
KRW 9780.0
(-1.81%)
KRW 9780.0
(-1.81%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -24.53 Billion KRW | -27.88% |
| 2022 | -19.94 Billion KRW | -8.84% |
| 2021 | -18.32 Billion KRW | -128.6% |
| 2020 | -8.01 Billion KRW | -49.12% |
| 2019 | -5.37 Billion KRW | 30.74% |
| 2018 | -7.76 Billion KRW | -1850.19% |
| 2017 | 443.57 Million KRW | 138.78% |
| 2016 | -1.14 Billion KRW | 89.14% |
| 2015 | -10.53 Billion KRW | -793.09% |
| 2014 | 1.51 Billion KRW | 146.23% |
| 2013 | -3.28 Billion KRW | 22.85% |
| 2012 | -4.26 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -6.24 Billion KRW | -10.58% |
| 2024 Q1 | -5.64 Billion KRW | 34.77% |
| 2023 Q2 | -6.65 Billion KRW | -130.16% |
| 2023 Q4 | -8.65 Billion KRW | -34.8% |
| 2023 Q3 | -6.42 Billion KRW | 3.56% |
| 2023 FY | -25.51 Billion KRW | -27.88% |
| 2023 Q1 | -2.89 Billion KRW | 66.71% |
| 2022 Q2 | -4.69 Billion KRW | -359.94% |
| 2022 Q4 | -8.68 Billion KRW | -56.26% |
| 2022 Q3 | -5.56 Billion KRW | -18.44% |
| 2022 FY | -19.94 Billion KRW | -8.84% |
| 2022 Q1 | -1.02 Billion KRW | 89.53% |
| 2021 Q2 | -3.53 Billion KRW | -33.44% |
| 2021 Q4 | -9.74 Billion KRW | -303.32% |
| 2021 Q1 | -2.65 Billion KRW | -43.31% |
| 2021 Q3 | -2.41 Billion KRW | 31.72% |
| 2021 FY | -18.32 Billion KRW | -128.6% |
| 2020 Q2 | -1.61 Billion KRW | 39.47% |
| 2020 FY | -8.01 Billion KRW | -49.12% |
| 2020 Q4 | -1.85 Billion KRW | 1.33% |
| 2020 Q3 | -1.87 Billion KRW | -15.93% |
| 2020 Q1 | -2.67 Billion KRW | -204.53% |
| 2019 Q3 | -4.49 Billion KRW | -88.54% |
| 2019 Q2 | -2.38 Billion KRW | -127.72% |
| 2019 Q1 | -1.04 Billion KRW | 63.17% |
| 2019 FY | -5.37 Billion KRW | 30.74% |
| 2019 Q4 | 2.55 Billion KRW | 156.84% |
| 2018 Q4 | -2.84 Billion KRW | -64.52% |
| 2018 Q3 | -1.72 Billion KRW | 9.06% |
| 2018 Q2 | -1.9 Billion KRW | -46.31% |
| 2018 Q1 | -1.29 Billion KRW | -288.07% |
| 2018 FY | -7.76 Billion KRW | -1850.19% |
| 2017 Q1 | -238.11 Million KRW | -119.42% |
| 2017 Q3 | -248.93 Million KRW | -203.97% |
| 2017 Q4 | 691.19 Million KRW | 377.66% |
| 2017 Q2 | 239.43 Million KRW | 200.55% |
| 2017 FY | 443.57 Million KRW | 138.78% |
| 2016 Q3 | -1.51 Billion KRW | -202.71% |
| 2016 Q4 | 1.22 Billion KRW | 181.04% |
| 2016 FY | -1.14 Billion KRW | 89.14% |
| 2016 Q2 | -499.78 Million KRW | -39.9% |
| 2016 Q1 | -357.25 Million KRW | 84.66% |
| 2015 Q1 | -1.48 Billion KRW | -224.53% |
| 2015 Q2 | -4.66 Billion KRW | -214.34% |
| 2015 Q4 | -2.32 Billion KRW | -13.49% |
| 2015 Q3 | -2.05 Billion KRW | 56.03% |
| 2015 FY | -10.53 Billion KRW | -793.09% |
| 2014 Q1 | -66.21 Million KRW | 96.17% |
| 2014 Q2 | 235.49 Million KRW | 455.62% |
| 2014 FY | 1.51 Billion KRW | 146.23% |
| 2014 Q3 | 158.11 Million KRW | -32.86% |
| 2014 Q4 | 1.19 Billion KRW | 654.17% |
| 2013 Q2 | -648.46 Million KRW | 2.12% |
| 2013 Q3 | -246.24 Million KRW | 62.03% |
| 2013 Q4 | -1.73 Billion KRW | -602.79% |
| 2013 FY | -3.28 Billion KRW | 22.85% |
| 2013 Q1 | -662.5 Million KRW | 74.6% |
| 2012 Q3 | -917.31 Million KRW | 0.0% |
| 2012 FY | -4.26 Billion KRW | 0.0% |
| 2012 Q4 | -2.6 Billion KRW | -184.38% |
| Name | Operating Income | Operating Income Difference |
|---|